Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 143

1.

Prediction of response to interferon α-1b in HBeAg-positive chronic hepatitis B: a clue from HBsAg levels.

Ma Q, Qin B, Gong X, Lu X.

Eur J Gastroenterol Hepatol. 2013 Jul;25(7):820-4. doi: 10.1097/MEG.0b013e32835ee611.

PMID:
23411867
2.

Quantitative hepatitis B surface antigen levels in patients with chronic hepatitis B after 2 years of entecavir treatment.

Fung J, Lai CL, Young J, Wong DK, Yuen J, Seto WK, Yuen MF.

Am J Gastroenterol. 2011 Oct;106(10):1766-73. doi: 10.1038/ajg.2011.253. Epub 2011 Aug 9.

PMID:
21826112
3.

Prediction of treatment-related HBsAg loss in HBeAG-negative chronic hepatitis B: a clue from serum HBsAg levels.

Manesis EK, Hadziyannis ES, Angelopoulou OP, Hadziyannis SJ.

Antivir Ther. 2007;12(1):73-82.

PMID:
17503750
4.

[Clinical observations of sequential interferon therapy following complete response to telbivudine treatment in chronic hepatitis B patients].

Zhang W, Sandeep KK, Zhang QF, Guo SH, Zhang DZ.

Zhonghua Gan Zang Bing Za Zhi. 2013 Aug;21(8):570-4. doi: 10.3760/cma.j.issn.1007-3418.2013.08.003. Chinese.

PMID:
24119734
5.

Quantitative serum HBsAg and HBeAg are strong predictors of sustained HBeAg seroconversion to pegylated interferon alfa-2b in HBeAg-positive patients.

Ma H, Yang RF, Wei L.

J Gastroenterol Hepatol. 2010 Sep;25(9):1498-506. doi: 10.1111/j.1440-1746.2010.06282.x.

PMID:
20796146
6.

Prediction of off-treatment response to lamivudine by serum hepatitis B surface antigen quantification in hepatitis B e antigen-negative patients.

Chan HL, Wong GL, Chim AM, Chan HY, Chu SH, Wong VW.

Antivir Ther. 2011;16(8):1249-57. doi: 10.3851/IMP1921.

PMID:
22155906
7.

On-treatment serum HBsAg level is predictive of sustained off-treatment virologic response to telbivudine in HBeAg-positive chronic hepatitis B patients.

Cai W, Xie Q, An B, Wang H, Zhou X, Zhao G, Guo Q, Gu R, Bao S.

J Clin Virol. 2010 May;48(1):22-6. doi: 10.1016/j.jcv.2010.02.014. Epub 2010 Mar 15.

PMID:
20233672
8.

A predictive scoring system for the seroclearance of HBsAg in HBeAg-seronegative chronic hepatitis B patients with genotype B or C infection.

Liu J, Lee MH, Batrla-Utermann R, Jen CL, Iloeje UH, Lu SN, Wang LY, You SL, Hsiao CK, Yang HI, Chen CJ.

J Hepatol. 2013 May;58(5):853-60. doi: 10.1016/j.jhep.2012.12.006. Epub 2012 Dec 13.

PMID:
23246508
9.

Reduction of hepatitis B surface antigen levels and hepatitis B surface antigen seroclearance in chronic hepatitis B patients receiving 10 years of nucleoside analogue therapy.

Seto WK, Wong DK, Fung J, Huang FY, Lai CL, Yuen MF.

Hepatology. 2013 Sep;58(3):923-31. doi: 10.1002/hep.26376. Epub 2013 Jul 24.

PMID:
23468172
10.

Predictive value of interferon-gamma inducible protein 10 kD for hepatitis B e antigen clearance and hepatitis B surface antigen decline during pegylated interferon alpha therapy in chronic hepatitis B patients.

Wang Y, Zhao C, Zhang L, Yu W, Shen C, Wang W, Zhen Z, Zhou J.

Antiviral Res. 2014 Mar;103:51-9. doi: 10.1016/j.antiviral.2014.01.001. Epub 2014 Jan 10.

PMID:
24418572
11.

Hepatitis B surface antigen levels during the natural history of chronic hepatitis B: a perspective on Asia.

Nguyen T, Thompson AJ, Bowden S, Croagh C, Bell S, Desmond PV, Levy M, Locarnini SA.

J Hepatol. 2010 Apr;52(4):508-13. doi: 10.1016/j.jhep.2010.01.007. Epub 2010 Feb 16.

PMID:
20206400
12.

Experimental HBsAg/anti-HBs complex assay for prediction of HBeAg loss in chronic hepatitis B patients treated with pegylated interferon and adefovir.

de Niet A, Jansen L, Zaaijer HL, Klause U, Takkenberg B, Janssen HL, Chu T, Petric R, Reesink HW.

Antivir Ther. 2014;19(3):259-67. doi: 10.3851/IMP2707. Epub 2013 Nov 21.

PMID:
24256626
13.

Serum hepatitis B surface antigen levels predict surface antigen loss in hepatitis B e antigen seroconverters.

Tseng TC, Liu CJ, Su TH, Wang CC, Chen CL, Chen PJ, Chen DS, Kao JH.

Gastroenterology. 2011 Aug;141(2):517-25, 525.e1-2. doi: 10.1053/j.gastro.2011.04.046. Epub 2011 Apr 28.

PMID:
21672542
14.

Factors associated with serum hepatitis B surface antigen levels and its on-treatment changes in patients under lamivudine therapy.

Chen J, Wang Z, Zhou B, Wang Y, Hou J.

Antivir Ther. 2012;17(1):71-9. doi: 10.3851/IMP1925.

PMID:
22267471
15.

HBsAg and HBeAg in the prediction of a clinical response to peginterferon α-2b therapy in Chinese HBeAg-positive patients.

Yang S, Xing H, Wang Y, Hou J, Luo D, Xie Q, Ning Q, Ren H, Ding H, Sheng J, Wei L, Chen S, Fan X, Huang W, Pan C, Gao Z, Zhang J, Zhou B, Chen G, Wan M, Tang H, Wang G, Yang Y, Xu D, Dong P, Wang Q, Wang J, Bognar FA, Xu D, Cheng J.

Virol J. 2016 Oct 28;13(1):180.

16.

Pretreatment serum HBsAg-to-HBV DNA ratio predicts a virologic response to entecavir in chronic hepatitis B.

Song JC, Min BY, Kim JW, Kim JY, Kim YM, Shin CM, Lee SH, Hwang JH, Jeong SH, Kim N, Lee DH.

Korean J Hepatol. 2011 Dec;17(4):268-73. doi: 10.3350/kjhep.2011.17.4.268.

17.

Sustained responses and loss of HBsAg in HBeAg-negative patients with chronic hepatitis B who stop long-term treatment with adefovir.

Hadziyannis SJ, Sevastianos V, Rapti I, Vassilopoulos D, Hadziyannis E.

Gastroenterology. 2012 Sep;143(3):629-636.e1. doi: 10.1053/j.gastro.2012.05.039. Epub 2012 May 31.

PMID:
22659218
18.

Response to interferon-alpha in chronic hepatitis B patients with and without precore mutant strain and effects on HBsAg titers.

Akhan SC, Yulugkural Z, Vahaboglu H.

Chemotherapy. 2007;53(6):402-6. Epub 2007 Oct 12.

PMID:
17934260
19.

Prediction of response to entecavir therapy in patients with HBeAg-positive chronic hepatitis B based on on-treatment HBsAg, HBeAg and HBV DNA levels.

Shin JW, Jung SW, Park BR, Kim CJ, Eum JB, Kim BG, Jeong ID, Bang SJ, Lee SH, Kim SR, Park NH.

J Viral Hepat. 2012 Oct;19(10):724-31. doi: 10.1111/j.1365-2893.2012.01599.x. Epub 2012 Mar 15.

PMID:
22967104
20.

The importance of the serum quantitative levels of hepatitis B surface antigen and hepatitis B e antigen in children with chronic hepatitis B.

Demirören K, Kocamaz H, Doğan Y.

Turk J Gastroenterol. 2015 Jan;26(1):36-41. doi: 10.5152/tjg.2015.4636.

Supplemental Content

Support Center